首页> 外文期刊>Peptides: An International Journal >B-type natriuretic peptide expression and cardioprotection is regulated by Akt dependent signaling at early reperfusion
【24h】

B-type natriuretic peptide expression and cardioprotection is regulated by Akt dependent signaling at early reperfusion

机译:B型利钠肽的表达和心脏保护受到早期再灌注时Akt依赖信号的调节

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Exogenously administered B-type natriuretic peptide (BNP) has been shown to offer cardioprotection through activation of particulate guanylyl cycla se (p GC), protein kina se G (PKG) and KATp channel opening. The current study explores if cardioprotection afforded by short intermittent BNP administration involves PI3K/Akt/p70s6k dependent signaling, and whether this signaling pathway may participate in regulation of BNP mRNA expression at early reperfusion. Isolated Langendorff perfused rat hearts were subjected to 30 min of regional ischemia and 120 min of reperfusion (IR). Applying intermittent 3 x 30s infusion of BNP peptide in a postconditioning like manner (BNPpost) reduced infarct size by >50% compared to controls (BNPpost 17 I 2% vs. control 42 I 4%, p <0.001). Co-treatment with inhibitors of the PI3K/Akt/p70s6k pathway (wortmannin, SH-6 and rapamycin) completely abolished the infarct-limiting effect of BNP postconditioning (BNPpost +/- Wi 36 I 5%, BNPpost +/- SH-6 41 I 4%, BNPpost +/- Rap 37 I 6% vs. BNPpost 17 I 2%, p < 0.001). Inhibition of natriuretic peptide receptors (NPR) by isatin also abrogated BNPpost cardioprotection (BNPpost +/- isatin 46 +/- 2% vs. BNPpost 17 +/- 2%, p <0.001). BNPpost also significantly phosphorylated Akt and p70s6k at early reperfusion, and Akt phosphorylation was inhibited by SH-6 and isatin. Myocardial BNP mRNA levels in the area at risk (AA) were significantly elevated at early reperfusion as compared to the non-ischemic area (ANA) (Ctr(M) 2.7 +/- 0.5 vs. Ctr(ANA) 1.2 +/- 0.2, p <0.05) and the ischemic control tissue (Ctr(M) 2.7 +/- 0.5 vs. ischemia 1.0 +/- 0.1, p <0.05). Additional experiments also revealed a significant higher BNP mRNA level in ischemic postconditioned (I-post) hearts as compared to ischemic controls (I-post 6.7 +/- 1.3 vs. ischemia 1.0 +/- 0.2, p < 0.05), but showed no difference from controls run in parallel (Ctr 5.4 +/- 0.8). Akt inhibition by SH-6 completely abrogated this elevation (I-post 6.7 +/- 1.3 vs. I-post +/- SH6 1.8 +/- 0.7, p <0.05) (Ctr 5.4 +/- 0.8 vs. SH-6 1.5 +/- 0.9, p <0.05). In conclusion, Akt dependent signaling is involved in mediating the cardioprotection afforded by intermittent BNP infusion at early reperfusion, and may also participate in regulation of reperfusion induced BNP expression. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://cleativecommons.org/licenses/by-nc-nd/4.0/).
机译:已显示外源性B型利钠肽(BNP)可通过激活鸟嘌呤基环己基环(p GC),蛋白激酶G(PKG)和KATp通道开放来提供心脏保护作用。目前的研究探讨了短期间歇BNP给药所提供的心脏保护作用是否涉及PI3K / Akt / p70s6k依赖性信号传导,以及该信号传导途径是否可能参与早期再灌注时BNP mRNA表达的调节。离体的Langendorff灌注大鼠心脏经受30分钟的局部缺血和120分钟的再灌注(IR)。与对照相比,以类似后处理的方式(BNPpost)间歇性地输注BNP肽3 x 30s可使梗死面积减少50%以上(BNPpost 17 I 2%,对照42 I 4%,p <0.001)。与PI3K / Akt / p70s6k途径抑制剂(渥曼青霉素,SH-6和雷帕霉素)的共同治疗完全消除了BNP后处理的梗塞限制作用(BNPpost +/- Wi 36 I 5%,BNPpost +/- SH-6 41 I 4%,BNPpost +/- Rap 37 I 6%,而BNPpost 17 I 2%,p <0.001)。靛红抑制利钠肽受体(NPR)也废除了BNPpost的心脏保护作用(BNPpost +/- isatin 46 +/- 2%vs. BNPpost 17 +/- 2%,p <0.001)。 BNPpost在早期再灌注时也会显着磷酸化Akt和p70s6k,SH-6和isatin抑制Akt磷酸化。与非缺血区域(ANA)相比,早期再灌注时,处于危险区域(AA)的心肌BNP mRNA水平显着升高(Ctr(M)2.7 +/- 0.5 vs. Ctr(ANA)1.2 +/- 0.2 ,p <0.05)和缺血性对照组织(Ctr(M)2.7 +/- 0.5 vs.缺血1.0 +/- 0.1,p <0.05)。额外的实验还显示,与缺血对照组相比,缺血后适应(I后)心脏的BNP mRNA水平显着更高(I后6.7 +/- 1.3与缺血1.0 +/- 0.2,p <0.05),但未显示与对照平行执行的差异(Ctr 5.4 +/- 0.8)。 SH-6对Akt的抑制作用完全消除了这种升高(I-post 6.7 +/- 1.3 vs. I-post +/- SH6 1.8 +/- 0.7,p <0.05)(Ctr 5.4 +/- 0.8 vs. SH-6 1.5 +/- 0.9,p <0.05)。总之,依赖Akt的信号传导参与了早期再灌注时间歇性BNP输注所提供的心脏保护作用,并且也可能参与了再灌注诱导的BNP表达的调节。 (C)2015作者。由Elsevier Inc.发行。这是CC BY-NC-ND许可下的开放获取文章(http://cleativecommons.org/licenses/by-nc-nd/4.0/)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号